Telomeres of hematopoietic cells shorten with age, possibly contributing to the aging-associated hematopoietic pathology (immunosenescence, malignant transformation). Accelerated telomere shortening is seen with replicative stress, such as during administration of serial chemotherapy cycles for the treatment of childhood cancer. To define the long-term consequences of pediatric cancer treatment on hematopoietic cell telomere length, we undertook a prospective 4-year follow-up study of a 61-patient cohort of pediatric malignancies in a community-based setting. We found that mononuclear cells (MNC) and granulocytes of children with standard-risk acute lymphoblastic leukemia (ALL) suffered minimal telomere shortening throughout therapy (less than 1 kbp; average follow-up, 20 months), while those of children with solid tumors showed greater and more heterogenous telomere attrition (0.5-2.8 kbp, average follow-up, 9 months). In addition, we evaluated the role of telomerase, the enzyme commonly up-regulated in pediatric leukemic and solid tumor cells for telomere length maintenance, as a disease marker. Serial determinations of telomerase in MNC were useful to confirm disease remission in leukemia, but play no role in the follow-up of children with solid tumors.
Introduction
Telomeres, the highly specialized nucleoprotein structures that cap chromosomes, are involved in maintenance of genomic stability and DNA repair. [1] [2] Human telomeric DNA consists of tandem TTAGGG repeats that span 5-15 kbp and end in a single-stranded 3′ overhang that folds back into doublestranded telomeric DNA. 3 Telomeric proteins, such as TRF1, TRF2 and tankyrase, are required to maintain the higher-order structure of telomeric heterochromatin and to prevent recognition of chromosome ends as damaged DNA. 3 In most human somatic cells, telomere length decreases by 50-150 bp per cell division, as a consequence of incomplete replication of telomeric DNA, the so-called 'end-replication problem'. 1 Critical telomere shortening triggers the cellular senescence programme in vitro 4 and probably also in vivo. 5 In addition, short telomeres may contribute to carcinogenesis by promoting chromosomal instability in cells with deficient checkpoints. 6 Telomere shortening can be prevented or slowed by upregulation of telomerase, a reverse transcriptase that binds to the single-stranded telomeric 3′ overhang and adds new telomeric repeats during the S phase of the cell cycle using a builtin RNA as a template. 7, 8 Human hematopoietic stem cells and lymphocytes express telomerase in a developmentally regulated manner. 9 Stem cells up-regulate telomerase when stimulated to generate bone marrow precursors; 10 lymphocytes do so during clonal expansion. 11 However, despite telomerase up-regulation, telomere shortening is not fully prevented, [10] [11] [12] [13] [14] and may lead to loss of proliferative ability in hematopoietic cells. 5 This is supported by the observation that telomere shortening is increased in the following situations: (1) at times of highest proliferative demand in physiological conditions, such as during expansion of the hematopoietic system during fetal life 15 and in the first years of life; [16] [17] [18] (2) in children with genetic diseases that combine accelerated telomere shortening of hematopoietic cells and clinical hematopoietic failure, such as dyskeratosis congenita, 19 idiopathic aplastic anemia, 20 Fanconi anemia 21 and ataxia-telangiectasia; 22 (3) with hematopoietic reconstitution after therapeutic administration of cytotoxic agents (bone marrow transplantation, [23] [24] [25] [26] [27] [28] [29] [30] chemotherapy administration. 31 In this latter setting, the reported rate of shortening has varied in the different studies; in the transplant setting, telomere shortening has been shown to take place mainly in the first year posttransplant. 26, 29 Furthermore, the clinical impact of therapy-related telomere shortening, if any, has not been established.
All transformed cells develop mechanisms to maintain telomeres beyond the critical length that signals entry into senescence. Up-regulation of the enzyme telomerase is found in over 85% of human cancers, 32 and overexpression is commonly found in leukemic cell lines and in peripheral blood and bone marrow samples of patients with leukemia. 30, [33] [34] [35] [36] [37] [38] Upon treatment, telomerase activity reportedly decreases, due to either the elimination of the leukemic clone by cytotoxic agents 30, 35 and/or to enzyme down-regulation by noncytotoxic differentiating agents. 37 Furthermore, persistence of elevated levels of telomerase during remission has been associated with relapse in two patients with ALL, 38 pointing to telomerase as a marker of residual disease. These observations raise the question of whether determination of telomerase activity could be a helpful remission marker in a battery of routine follow-up tests in childhood leukemia and, by extension, in childhood nonhematological tumors.
We report here a 4-year follow-up study on a representative cohort of pediatric oncological patients from a single community-based institution. We extend our previously published short-term observations to the medium-term and analyze: (1) telomere length of PB and BM MNC and granulocytes at different stages of therapy; and (2) the role of measurements of telomerase activity in serial peripheral blood and bone marrow samples to determine disease status and prognosis.
Materials and methods

Patients
Eligible individuals were all children diagnosed with a malignant disease, myelodysplastic syndrome or dyshematopoiesis, and followed at the Pediatric Hematology/Oncology Section, Valhalla, New York. The research protocol was approved by the institutional IRB and all patients or their legal guardians signed an informed consent.
Between April 1996 and December 1999, 61 patients were enrolled. Peripheral blood and/or bone marrow specimens were obtained at diagnosis, during treatment and at routine follow-up visits after completion of therapy. Patient characteristics (diagnosis, treatment protocol, sex, age at diagnosis and time of follow-up) are summarized in Table 1 . For all patients, mean age at diagnosis was 5.5 ± 4.5 years (range, 8 months to 17 years), and mean time of follow-up was 23.4 ± 11.0 months (range, 6 to 36 months). The 61 patients were divided into six groups according to diagnosis: standard-risk ALL (n = 23), high-risk ALL (n = 8), AML (n = 6), Hodgkin's disease (n = 5), solid tumors (n = 14) and other hematological disorders (n = 5). Patients with acute lymphoblastic leukemia (ALL) were assigned to the standard-risk or high-risk categories according to standard criteria of age and leukemic burden. 39 Disease-specific age at diagnosis and time of follow-up are summarized in Table 2 . A total of 303 samples were analyzed for telomerase activity (115 BM samples, 188 PB samples). Of these, 39 (12.9%) were obtained at the time of diagnosis, 47 (15.5%) during induction chemotherapy, 42 (13.9%) during consolidation therapy, 139 (45.9%) during maintenance therapy, 29 (9.6%) off therapy and seven (2.3%) at the time of relapse. In addition, diagnostic and follow-up samples (maintenance and/or off therapy) of 24 patients (10 ALL, 9 solid tumors, 3 HD, 1 SAA) were analyzed for telomere length (Table 1 , indicated in column 1 with an asterisk).
Individual staging and chemotherapy regimens are summarized in Table 1 . In brief, patients with leukemia were treated according to their risk with either CCG-1952/BFM (standard risk) or CCG-1961/augmented BFM (high risk). All six patients with AML were treated with CCG-2961. The six patients with Hodgkin's disease (HD) were treated as per CCG-5942; two of them also received multiple courses of ICE. Of patients with solid tumors, five were enrolled in the National Wilms Tumor Study V (NWTS V) and the remaining patients received various combinations of alkylating agent-based therapy. Two patients with brainstem tumors received brain radiation therapy followed by autologous stem cell infusion after thiotepa and carboplatinum. Five patients with nonleukemic hematological disorders were treated with immunosuppressive agents (2 SAA, 2 FEL, 1 eosinophilic granuloma). Nine children (2 HD, 7 solid tumors) received autologous stem cells after myeloablative chemotherapy (see Table 1 ).
Isolation of mononuclear cells and granulocytes from peripheral blood and bone marrow specimens
Peripheral blood (PB) or bone marrow (BM) samples were drawn in heparinized tubes and processed within 24 h. Buffy coats were diluted in 1% FCS/PBS and laid over a density gradient (Percoll; Amersham Pharmacia Biotech, Uppsala, Sweden). Two distinct layers, corresponding to MNC and GN, were separated by centrifugation at 2000 r.p.m. for 30 min, washed with PBS, depleted of red cells, and snap-frozen at −80°C. Purity of each fraction was assessed by cytospin of 10 5 cells of each fraction; purity was generally Ͼ90%. Cell viability was determined by trypan blue exclusion; viability was Ͼ90% in all samples.
TRF (terminal restriction fragments) assay
For DNA extraction, 1 to 10 million cells were resuspended in lysis buffer (100 mM NaCl, 10mM Tris, 25 mM EDTA, 0.5% SDS and proteinase K 0.1 mg/ml), incubated at 37°C overnight, extracted with an equal volume of phenol chloroform, and precipitated in 200 mM NaCl and cold ethanol. The DNA was washed once with 70% ethanol, air-dried and dissolved in TE. Five to 10 g of DNA were incubated with 2 U/g of the restriction endonucleases RsaI and MspI (Boehringer, Mannheim, Germany) at 37°C overnight. Completeness of digestion was assessed by electrophoresis of 0.5 g of digested DNA in 1% agarose gels. For determination of telomere length, digested DNA was separated in a 0.5% agarose gel at 75 V over 16 h. After electrophoresis, the gel was depurinated in 0.2 M HCl for 10 min, denatured in 1.5 M NaCl/0.5N NaOH for 30 min and neutralized in 1.5 M NaCl/0.5 M Tris pH 8.0 for 30 min. DNA was transferred to a nylon membrane (Nytran; Schleicher and Schuell, Dassel, Germany) in 10× SSC buffer overnight. The membrane was prehybridized in 6× SSPE, 0.5% SDS, 5× Denhardts, 20 g/ml tRNA(transfer ribonucleic acid) type X (Sigma, Steinheim, Germany) at 55°C for 2 h, then hybridized overnight at 55°C in 6× SSPE, 1% SDS with 1 g of the telomeric probe (TTAGGG) 4 (Gibco BRL), previously end-labeled with ATP-P 32 . Washing consisted of three 15-min washes with 6× SSPE, 0.1% SDS at room temperature. Washed membranes were exposed to phosphoimager plates for 6 to 18 h and telomere length determined using MacBas softaware, v2.1.
Measurement of telomerase activity by the TRAP assay
Protein extracts and telomerase activity determinations were performed as originally described by Kim et al 32 with the modifications of Wright et al. 40 For protein extraction, cells were incubated in lysis buffer (10 mM Tris-HCl pH 7.5, 1 mM MgCl 2 , 1 mM EGTA, 0.1 mM PMSF, 5 mM ␤-mercaptoethanol, 0.5% CHAPS, 10% glycerol) for 30 min on ice, centrifuged at 13 000 r.p.m. for 15 min at 4°C and the concentration of protein in the supernatant measured using Biorad Protein Solution and adjusted to a working concentration of 1 g/l. To allow for the telomerase present in the sample to extend the telomere-like primer TS, 2 g of protein were incubated at room temperature for 30 min with a PCR mix consisting of 10× TRAP buffer (200 mM Tris-HCl pH 8.3, 15 mM MgCl 2 , 630 mM KCl, 0.5% Tween 20, 10 mM EGTA, 1 mg/ml BSA fraction V), 1 g of P 32 end-labeled TS primer (5′-AATCCGTCGAGCAGAGTT-3′), 0.1 g RP primer (5′-GCGCGG(CTTACC) 3 CTAACC-3′), 0.1 g NT primer (5′-ATCGCTTCTCGGCTTTTT-3′), 0.01 amol TSNT primer (5′-AATCCGTCGAGCAGAGTTAAAAGGCCGAGAAGCGAT-3′), 2.5 mM d NTP (dCTP, dGTP, dTTP) and Taq DNA polymerase 2 U (Fisher Scientific, Pittsburg, PA, USA). The same mix was added to 2 l of H 2 O (negative control) or 2 l of 0.1 amol/l of the R8 quantitation standard oligonucleotide (5′-AATCCGTCGAGCAGAGTTAG(GGTTAG) 7 -3′) (positive control). The TSNT primer is an internal control. The extension products were amplified by PCR (94°C, 60°C and 72°C for 30 s each, for 30 cycles). PCR products were separated in a 12% polyacrylamide gel and exposed to a phosphoimager plate for 1 h. Intensity of signal for the telomeric bands and the internal control was quantified with MacBas software, Fuji, Japan. The corrected telomerase activity was calculated as TPG (total product generated) using the formula:
) × 100, where T = activity of telomeric bands; B = background, or activity in the H 2 O lane; It = activity of the internal control of the sample; T R8 = activity of the telomeric bands of the R8 control; It R8 = activity of the R8 internal control. As a second reference, we included 2 g of protein extract from a neuroblastoma cell line known to express high levels of telomerase (SK-N-SH cell line, a gift of Dr Nai-Kong L Cheung, Memorial Sloan-Kettering, New York, NY, USA) and the activity of each sample was calculated as a percentage of the neuroblastoma activity in the same gel. To ensure the specificity of the reaction, selected samples were incubated with RNAse for 10 min prior to the extension step. We arbitrarily defined telomerase activity of each sample in comparison to the neuroblastoma control as weak (Ͻ10%), moderate (10-50%) and high (Ͼ50%). All results are averages of three assays.
Results
Telomere shortening in hematopoietic cells of children treated for leukemia
We had previously shown that in MNC samples obtained at diagnosis of children with leukemia, TRFs display two separate peaks: a high molecular weight peak corresponding to the residual nonleukemic hematopoietic cells and a lower molecular weight peak corresponding most likely to the leukemic clone. 31 This leukemic lower peak disappears with treatment, and therefore we have focused on nonleukemic cell TRF measurements for this follow-up study.
In our series, telomere length in PB MNC in 10 patients with ALL decreased from 9.8 ± 0.9 kbp at diagnosis to 9.0 ± 1.4 kbp at latest follow-up (follow-up period, 20 months; average telomere loss per month per patient, 40 bp). Similarly, granulocyte telomere length decreased from 9.3 ± 1.6 kbp to 8.7 ± 1.8 kbp at follow-up (average, 30 bp per month per patient). Individual measurements according to stage of treatment are shown in Table 3 and Figure 1a . Telomere length at induction was not measured in most patients due to the very low WBC counts at that period of treatment (in these samples, cell number was often suffcient for determination of telomerase actiivity, but not for telomere length measurement). The maintenance period was arbitrarily divided in early and late maintenance, with the cutoff at 1 year after the start of maintenance. Remarkably, and although variation from patient to patient existed, telomere loss in children that had either completed treament or were about to do so was usually below 
Telomere length in children with solid tumors
Patients with solid tumors comprise a more heterogenous group regarding diagnosis and cumulative myelotoxicity of therapy (Table 1) . We measured telomere length in PB MNC and granulocyte samples of nine patients at diagnosis and at Leukemia a mean of 9 months (3-17 months) thereafter, when most patients were receiving maintenance chemotherapy or were already off therapy. As previously described, 31 telomere length at diagnosis correlated with patient age for both the MNC (r 2 = 0.7) and the granulocyte fractions (r 2 = 0.7) (Figure 1b ). On average, MNC telomeres were slightly longer and more heterogenous in length than granulocyte telomeres from the same blood extraction (10.4 ± 1.5 kbp (range, 7.8 to 11.1 kbp) vs 10.2 ± 1.1 kbp (range, 7.8-12 kbp), respectively). Individual measurements according to stage of treatment are shown in Table 4 and plotted in Figure 1a . PB MNC telomere length was 10.9 kbp at diagnosis, 10.1 kbp at maintenance and 9.7 kbp off therapy (100 bp per month of treatment per patient). Telomere length in the granulocyte fraction was slightly lower than in the MNC fraction and decreased with treatment (diagnosis, 10.4; maintenance, 9.4; maintenance 9.4; n = 4; 80 bp per month of treatment per patient). Although a trend to shortening was evident (see dot plots in Figure 1a ; compare to ALL in same figure), differences between telomere length at diagnosis and off therapy were not statistically significant for either MNC or granulocytes (t test, P = 0.15 and P = 0.11, respectively). Figure 2b shows representative TRFs.
Thus, intensified treatment protocols for solid tumors of childhood result in greater telomere shortening per unit of time than longer, less intensive protocols used for leukemia, although significant individual variation was observed.
Telomere length was also measured in three patients with HD. Telomere length at diagnosis and off therapy was: 6. In addition, we measured telomere length in a 6-year-old girl with SAA (patient 57). Telomere length of the granulocyte fraction at diagnosis was 9.3 kbp. After ATG/CSA treatment, telomere length was 8.5 kbp, a greater rate of attrition than expected for that time interval (8 months). 
Leukemia
Telomerase activity as a marker of leukemic burden and of disease remission
To measure telomerase activity, we used the highly specific and sensitive PCR-based TRAP assay. A positive result in the TRAP assay correlates closely with the level of expression of hTERT, the catalytic subunit of telomerase, by RT-PCR of leukemic cells. 41 Furthermore, both assays have been shown to be equally predicitive of disease outcome in patients with neuroblastoma. 42 For tumor cells expressing high levels of telomerase, the assay is sensitive enough to detect a minimum of 10 positive cells per extract. 32 Acute lymphoblastic leukemia (ALL) is the most common pediatric oncological diagnosis in a community-based practice (about half of the total diagnosis in our series, Table 1 ). We followed 31 children with ALL (23 standard risk ALL, 8 high risk ALL) for 23.3 ± 10.7 and 20.7 ± 9.3 months, respectively (Table 2 ). Diagnostic and follow-up peripheral blood extractions and bone marrow aspirates were analyzed for telomerase activity using the TRAP assay on the mononuclear cell fraction (5.7 ± 3.7 samples per patient for patients with standard risk ALL and 6.5 ± 2.4 samples/patient for high-risk patients). Samples were grouped under four categories for analysis: diagnosis, induction/consolidation, maintenance and post-therapy.
For peripheral blood samples of children with standard-risk ALL, telomerase activity, expressed as percentage of activity of a neuroblastoma control, was 23.81 ± 22.55% (range, 2-68) at diagnosis, 5.8 ± 8.1% (range, 0.6-20) at induction/consolidation; 1.8 ± 2.9% (range, 0-10) at maintenance and 1.7 ± 2.9% (range, 0-5) off therapy. Group values were statistically significant (P Ͻ 0.05) when comparing diagnostic values with those of either induction, maintenance or off therapy (Figure 3a) . For high-risk ALL, telomerase activity was 72 ± 96% (20-216, n = 4) at diagnosis; 2 ± 1.7% at induction/consolidation (0-3, n = 3) and 0.7 ± 0.6% (0-1.6, n = 5) during maintenance chemotherapy. Levels of telomerase activity in high risk patients were not statistically significant from low-risk patients at any phase of treatment, including diagnosis (P = 0.38). Like PB samples, bone marrow specimens showed high levels of telomerase activity at diagnosis and low levels throughout and after treatment. At all phases of treatment, BM specimens tended to show higher levels of telomerase, probably reflecting a higher leukemic load initially and a higher proportion of telomerase-expressing proliferating progenitors later (Figure 3b) . However, the differences were not statistically significant (P = 0.35). None of the children relapsed during the time of follow-up by standard criteria (pathological examination of peripheral blood and bone marrow samples). Therefore, we could not evaluate the role of telomerase activity as a marker of minimal residual disease in this setting.
Activation of telomerase has also been described by us and others in the second most common childhood leukemia, AML. 30, 41, 43 Furthermore, drug-induced myeloblast differentiation leads to telomerase down-regulation. 43 In our six patients with AML, telomerase activity was 25 ± 5.0% at diagnosis , 2.5 ± 0.7% at induction/consolidation, 2.6 ± 0.8% at maintenance and 2.4 ± 1.0% off-therapy. No statistically significant differences were found when comparing levels of telomerase activity in ALL and AML specimens (data not shown). One child relapsed off therapy; telomerase activity was 85% of neuroblastoma control at initial diagnosis and 23% at relapse.
We also investigated the level of telomerase activity in nonleukemic hematological disorders. Telomerase activity is reportedly increased in about half of Hodgkin's disease primary specimens. 44, 45 In our series, telomerase activity in PB of five children with HD was low to negligible, regardless of staging, and did not predict relapse in one patient. Additionally, we measured telomerase activity in BM specimens of children with aplastic bone marrow disorders. Interestingly, a 7-year-old female with bone marrow aplasia displayed very high levels of telomerase, similar to a tumor control, while in the remaining four patients telomerase activity was very low.
Peripheral blood telomerase activity as a disease marker in nonhematological childhood cancer
Telomerase up-regulation has been reported in a series of the most common pediatric solid tumors, such as brain tumors, neuroblastoma, Wilm's tumor and bone and soft tissue sarcomas. 42, [46] [47] [48] [49] All of the above tumors may disseminate hematogenously, and metastatic spread is a main determinant of prognosis. Therefore, detection of tumor-derived telomerasepositive cancer cells in routine peripheral blood analysis would be of importance for staging and treatment response evaluation.
We tested telomerase activity in 38 PB samples (average, 2.7 samples per patient) and six BM samples of 14 patients (see Tables 1 and 2 for details). Unlike our observation in leukemia, telomerase activity in peripheral blood MNC was low to negligible at all stages of disease (Figure 3a and b, for example). BM samples displayed higher telomerase activity than PB samples, but in the range of control bone marrow samples from healthy children (data not shown). One child with stage IV Wilm's tumor relapsed off therapy, but telomerase activity in a PB sample obtained at the time of relapse was not increased either.
Taken together, these results suggest that determination of telomerase activity may be a valuable marker of disease remission in leukemia, but do not support a role in the follow- up of children with HD or solid tumors (a summary by disease and stage of treatment is shown in Figure 3c ).
Discussion
Adamson et al 50 first reported short telomeres in pediatric leukemias and telomere shortening of PB MNC upon treatment.
Leukemia
It is now widely accepted that, in normal healthy individuals, hematopoietic cell telomeres shorten with age, although significant interindividual variability exists due to both genetic and environmental reasons. 8 It is also generally accepted that increased shortening rates correlate with periods of increased proliferative demand (ie first years of life, the posttransplant period). However, there is currently no consensus on the extent and the clinical significance of accelerated shortening, mainly due to the fact that most studies have focused on shortterm measurements or provide information on a small number of patients.
Nonmyeloablative sequential chemotherapy cycles for childhood cancer treatment pose an additional nonphysiological proliferative demand on bone marrow precursors, and can be viewed as an additional period of rapid telomere shortening during childhood. Because many children cured of malignancy in the last three decades are expected to have a normal lifespan, telomere evaluation at late stages of treatment or upon treatment completion is of particular interest. Patients in this study were treated with a wide range of chemotherapeutic agents and doses. Standard-risk ALL, the most common diagnostic category, is treated with a low-intensity nonmyeloablative regimen, although prolonged periods of maintenance chemotherapy are required. On the other hand, patients with solid tumors in advanced stages often require adjuvant chemotherapy and radiotherapy in addition to surgical removal of tumor. They typically receive high-intensity chemotherapy during shorter time periods. This is the subset of patients at highest risk of developing secondary malignancies: the cumulative risk of second malignancies is 2.5 to 8% in long-term survivors of childhood ALL and in survivors of childhood cancers of all types. 51, 52 Furthermore, the use of DNA-damaging agents, such as radiotherapy and alkylating agents, have been clearly established as independent risk factors for secondary tumors in pediatric patients. 53, 54 Although no data on telomere function was provided in these studies, the cytogenetic abnormalities observed might have been caused or aggravated by short or unstable telomeres. In this regard, it has been reported that cisplatin, a nonclassical alkylating agent often used for the treatment of childhood solid tumors, directly targets telomeric DNA. 55 In this conceptual framework, our observation that telomere length in hematopoietic cells at the end of treatment for standard-risk ALL is not significantly shorter than expected for age is reassuring. This result could be explained by a compensatory increase in telomerase activity in the bone marrow cells of these children, although recent data have shown no differences in the extent of telomerase up-regulation in human lymphocytes with age. 8 Alternatively, nonmyeloablative therapy spares hematopoietic stem cells with adequate telomere reserve that are able to compensate for the increased proliferative demand if needed. Whether this leads to a reduction in the stem cell pool cannot be answered by this study. Finally, it must be taken into account that the loss of hematopoietic replicative potential with age or after bone marrow transplant is dependent not only on intrinsic cell factors (ie hematopoietic cell telomere length), but also on multiple extrinsic factors, such as the production of appropriate mitogenic and chemotactic signals by the bone marrow microenvironment. 56 In patients with solid tumors, a greater telomere attrition was observed. However, the high degree of individual variation observed here suggests that, at least in some patients, remaining stem cells may well compensate for the loss of hematopoietic precursors associated with cancer treatment. Similar heterogeneity has been reported in a study of breast cancer patients treated with chemotherapy. 57 The question for these patients is, what is a safe range of telomere shortening, given the heterogeneity in telomere loss and the individual variation in telomere length observed even in healthy individuals? Most evidence linking telomere shortening to malignant transformation and immunosenescence comes from mouse models. Serial transplantation of murine hematopoietic cells induces telomere shortening and loss of potential in secondary recipients, 58 while overexpression of telomerase in murine hematopoietic cells prevents both. 59 Furthermore, telomerasedeficient mice with critically short telomeres show decreased hematopoietic stem cell function in in vitro assays, although repopulation in vivo is still achieved. 60 Regarding transformation, it has been shown that, although telomere shortening per se is not oncogenic, 61 murine cells with short telomeres are more sensitive to ionizing radiation 62 and short telomeres accelerate oncogenesis in mice lacking tumor suppressor genes, such as p53 63 or Apc. 64 However, there are significant differences between mouse and human cells in terms of telomere length and telomerase activity regulation, 65 and therefore these observations cannot be directly extrapolated to human disease. In human cells, a clear link between short telomeres and immunosenescence is lacking at the preset time, 66 although telomere shortening is accelerated in some (but not all) progeroid syndromes 67, 68 and in lymphocytes of children with Down syndrome, that manifest an 'aged-like' phenotype. Finally, the relationship between short telomeres and oncogenesis in human cells is supported by the study of several genetic diseases with accelerated telomere shortening, hematopoietic failure and cancer predisposition (Fanconi anemia, ataxia-telangiectasia), although the cause and effect cannot be separated in these diseases, since the molecular basis is not well understood. In addition, telomere shortening and/or instability has been reported in CML that progresses to accelerated phase, 69 in patients with MDS and high-risk characteristics 70 and in osteosarcoma cells. 71 Discussing telomere function in the context of length is too simplistic an approach. The measurements of telomere length reported here and in most studies to date are obtained using either the TRF or flow-FISH assays, that provide an average of thousands or millions of telomeres. 72 This type of analysis may underscore critical telomere shortening in individual chromosomes, which has been shown to be the main determinant of cell function. 73 Measurement of individual telomeres by FISH techniques in long-term survivors and correlation with chromosomal instability data are urgently needed to reach firm conclusions on the effect of cancer treatment on hematopoietic cell telomere length. Furthermore, telomere length is but one of many determinants of telomere function. The function of telomere-associated proteins (ie Ku, DNA-PKcs, p53 and many others), 74 many of which are also involved in DNA repair (ie response to radio and chemotherapy), will also be crucial to understand the telomere phenotype of children treated with chemotherapy.
Finally, our study confirms that down-regulation of telomerase correlates with clearance of the leukemic clone by standard pathology, but does not support a role for serial determination of telomerase activity in PB or BM samples of pediatric standard-risk leukemic patients or patients with solid tumors. However, its usefulness in the high-risk setting, where recurrence of disease is a more common event, remains to be elucidated.
